Calliditas Therapeutics AB (publ) EBITDA 2011-2026 | CALT

Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.^[1]

EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.

EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.

However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.

Annual EBITDA Calliditas Therapeutics AB (publ)

2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-524 M	-377 M	-26.1 M	-133 M	-84.6 M	-56.4 M	-51.3 M	-	-	-	-

All numbers in SEK currency

Indicator range from annual reports

Maximum	Minimum	Average
-26.1 M	-524 M	-179 M

Quarterly EBITDA Calliditas Therapeutics AB (publ)

2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-208 M	-	-	-159 M	-151 M	-	-	-66.6 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in SEK currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
-66.6 M	-208 M	-146 M

References

Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.

EBITDA of other stocks in the Drug manufacturers industry

Issuer	EBITDA	Price	% 24h	Market Cap	Country
Assertio Holdings ASRT	8.47 M	$ 19.29	0.42 %	$ 124 M	USA
Bausch Health Companies BHC	2.23 B	$ 5.42	1.21 %	$ 1.98 B	Canada
AcelRx Pharmaceuticals ACRX	-13.5 M	-	7.5 %	$ 6.35 M	USA
Adamis Pharmaceuticals Corporation ADMP	-23.6 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	-40 M	-	-	$ 754 M	USA
Canopy Growth Corporation CGC	-95.6 M	$ 1.02	1.7 %	$ 110 M	Canada
Avadel Pharmaceuticals plc AVDL	-39.7 M	-	-	$ 2.06 B	France
Cumberland Pharmaceuticals CPIX	3.06 M	$ 3.23	1.74 %	$ 45.4 M	USA
Cronos Group CRON	-176 M	$ 2.58	1.78 %	$ 1.36 B	Canada
Evolus EOLS	-25.2 M	$ 4.2	4.09 %	$ 271 M	USA
Catalent CTLT	-260 M	-	-	$ 11.5 B	USA
Agile Therapeutics AGRX	-19.8 M	-	10.11 %	$ 58.2 M	USA
Alimera Sciences ALIM	6.82 M	-	-	$ 142 M	USA
Athenex ATNX	-65.5 M	-	-23.39 %	$ 1.76 M	USA
Harrow Health HROW	31.8 M	$ 35.93	1.76 %	$ 1.32 B	USA
Eagle Pharmaceuticals EGRX	81.6 M	-	-39.89 %	$ 27.7 M	USA
DURECT Corporation DRRX	-36.9 M	-	-	$ 50.1 M	USA
Evoke Pharma EVOK	-7.43 M	-	-	$ 36.6 M	USA
HEXO Corp. HEXO	-85.5 M	-	2.45 %	$ 38.1 M	Canada
Endo International plc ENDP	306 M	-	-	$ 28.9 M	Irlanda
OrganiGram Holdings OGI	-91.8 M	$ 1.42	2.55 %	$ 402 M	Canada
Aurora Cannabis ACB	-283 M	$ 3.48	1.02 %	$ 86.3 M	Canada
Organogenesis Holdings ORGO	12.3 M	$ 2.35	4.69 %	$ 309 M	USA
Pacira BioSciences PCRX	5.41 M	$ 22.39	-1.37 %	$ 1.04 B	USA
Relmada Therapeutics RLMD	-59.1 M	$ 6.97	-0.29 %	$ 275 M	USA
Rockwell Medical RMTI	-2.5 M	$ 0.95	-0.71 %	$ 34.2 M	USA
SCYNEXIS SCYX	-16.1 M	$ 0.94	5.6 %	$ 46.9 M	USA
Solid Biosciences SLDB	-178 M	$ 7.91	5.61 %	$ 692 M	USA
Sundial Growers SNDL	-132 M	$ 1.36	-	$ 3.37 M	Canada
Sonoma Pharmaceuticals SNOA	-3.57 M	$ 2.28	-3.79 %	$ 2.83 M	USA
Tilray TLRY	-1.37 B	$ 6.78	3.44 %	$ 4.19 B	Canada
Veru VERU	-36.6 M	$ 2.41	5.24 %	$ 325 M	USA
Jupiter Wellness JUPW	654 K	-	-	$ 33.6 M	USA
Viatris VTRS	3.51 B	$ 13.4	-0.28 %	$ 16.1 B	USA
Lannett Company LCI	-142 M	-	1.15 %	$ 7.11 M	USA
Emergent BioSolutions EBS	-601 M	$ 8.28	0.61 %	$ 424 M	USA
Neoleukin Therapeutics NLTX	-100 M	-	-	$ 193 M	Canada
OptiNose OPTN	-22.3 M	-	-	$ 1.08 B	USA
PetIQ PETQ	81.6 M	-	1.64 %	$ 400 M	USA
PLx Pharma PLXP	-40.7 M	-	-27.8 %	$ 2.56 M	USA
ProPhase Labs PRPH	28.3 M	-	-	$ 5.07 M	USA
Radius Health RDUS	-53.2 M	-	-	$ 1.42 B	USA
Recro Pharma REPH	4.65 M	-	-4.76 %	$ 65.3 M	USA
cbdMD YCBD	-2.86 M	$ 0.75	0.76 %	$ 3.23 M	USA
Zomedica Corp. ZOM	-82.3 M	-	-0.21 %	$ 98 M	USA
Zynerba Pharmaceuticals ZYNE	-35 M	-	-	$ 55.5 M	USA
Tricida TCDA	-153 M	-	-	$ 3.25 M	USA
China Pharma Holdings CPHI	-1.74 M	$ 0.66	5.06 %	$ 2.83 M	China
TherapeuticsMD TXMD	-4.01 M	$ 2.1	5.0 %	$ 24.3 M	USA